Twin Capital Management Inc. Purchases New Stake in Halozyme Therapeutics, Inc. $HALO

Twin Capital Management Inc. purchased a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 11,261 shares of the biopharmaceutical company’s stock, valued at approximately $758,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Sierra Summit Advisors LLC bought a new stake in Halozyme Therapeutics during the 4th quarter valued at $844,000. PSP Research LLC bought a new position in Halozyme Therapeutics in the 4th quarter worth $540,000. Tredje AP fonden bought a new position in Halozyme Therapeutics in the 4th quarter worth $2,019,000. Handelsbanken Fonder AB raised its holdings in Halozyme Therapeutics by 52.4% in the 4th quarter. Handelsbanken Fonder AB now owns 591,869 shares of the biopharmaceutical company’s stock worth $39,833,000 after purchasing an additional 203,500 shares in the last quarter. Finally, Profund Advisors LLC raised its holdings in Halozyme Therapeutics by 46.6% in the 4th quarter. Profund Advisors LLC now owns 36,100 shares of the biopharmaceutical company’s stock worth $2,430,000 after purchasing an additional 11,469 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors.

Insider Transactions at Halozyme Therapeutics

In other news, COO Cortney Caudill sold 8,857 shares of the company’s stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $67.64, for a total value of $599,087.48. Following the sale, the chief operating officer directly owned 7,055 shares of the company’s stock, valued at $477,200.20. This represents a 55.66% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bernadette Connaughton sold 1,625 shares of the company’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $63.48, for a total transaction of $103,155.00. Following the completion of the sale, the director directly owned 38,498 shares in the company, valued at $2,443,853.04. This represents a 4.05% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 120,482 shares of company stock valued at $8,200,842 in the last three months. 2.50% of the stock is currently owned by company insiders.

Analyst Ratings Changes

HALO has been the subject of several research reports. Wells Fargo & Company upped their price objective on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a report on Thursday, February 19th. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Benchmark upped their price objective on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, February 19th. TD Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, February 18th. Finally, HC Wainwright upped their price objective on shares of Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. Seven equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $80.67.

Halozyme Therapeutics Stock Down 0.7%

NASDAQ:HALO opened at $68.52 on Friday. The firm’s 50-day moving average price is $65.70 and its 200-day moving average price is $68.75. The company has a market capitalization of $8.13 billion, a PE ratio of 24.65, a P/E/G ratio of 0.28 and a beta of 0.89. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 2.33. Halozyme Therapeutics, Inc. has a 1-year low of $51.06 and a 1-year high of $82.22.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.06. The firm had revenue of $376.71 million for the quarter, compared to the consensus estimate of $358.60 million. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The company’s revenue was up 42.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.11 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, equities analysts predict that Halozyme Therapeutics, Inc. will post 7.66 EPS for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.